ALK(SZ:002940)2022-04-28 16:00Financial Performance - The company's revenue for Q1 2022 was CNY 338,209,274.21, representing a 6.06% increase compared to CNY 318,879,719.41 in the same period last year[4] - Net profit attributable to shareholders was CNY 39,086,498.56, up 19.23% from CNY 32,782,577.42 year-over-year[4] - Basic earnings per share rose to CNY 0.41, a 20.59% increase from CNY 0.34 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 338,209,274.21, an increase of 6.6% compared to CNY 318,879,719.41 in Q1 2021[27] - Net profit for Q1 2022 reached CNY 42,077,608.52, representing a 15.5% increase from CNY 36,576,577.16 in Q1 2021[28] - Earnings per share for Q1 2022 were CNY 0.41, compared to CNY 0.34 in Q1 2021, indicating a growth of 20.6%[29] Cash Flow - The net cash flow from operating activities increased by 70.74%, reaching CNY 89,918,248.97 compared to CNY 52,662,779.65 in Q1 2021[12] - Total cash inflow from operating activities amounted to ¥456,326,128.89, while cash outflow was ¥366,407,879.92, resulting in a net inflow of ¥89,918,248.97[32] - The net cash flow from investing activities was -¥201,224,708.39, a significant decline from -¥42,650,301.10 in the previous year[33] - Cash inflow from financing activities totaled ¥122,000,000.00, while cash outflow was ¥331,880.05, leading to a net cash inflow of ¥121,668,119.95[33] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 2,245,359,613.67, reflecting a 7.76% increase from CNY 2,083,578,310.62 at the end of the previous year[4] - Total liabilities increased to CNY 726,146,304.21 in Q1 2022 from CNY 608,642,637.36 in Q1 2021, representing a rise of 19.3%[25] - The company's total non-current assets reached CNY 896,002,288.39 in Q1 2022, up from CNY 707,622,586.30 in Q1 2021, indicating a growth of 26.7%[25] Investments - The company reported a significant increase in long-term equity investments by 216.76%, totaling CNY 287,112,626.94 due to increased investments in joint ventures[10] - The company experienced a 371.80% increase in cash flow from investing activities, resulting in a net outflow of CNY 201,224,708.39, primarily due to increased investments in joint ventures[12] - The company plans to acquire a 12.55% stake in Hunan New He New Biopharmaceutical Co., Ltd. for RMB 20,000,000[18] - The company has completed the acquisition of 23.48% of Hunan Keri Biopharmaceutical Co., Ltd. for RMB 15,747,690[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,264[13] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., held a 35.44% stake in the company[13] - The company repurchased a total of 2,060,000 shares, representing 2.15% of the total share capital, with a total transaction amount of RMB 63,330,916[16] Operational Expenses - Total operating costs for Q1 2022 were CNY 292,776,746.73, up from CNY 281,195,280.82 in the same period last year, reflecting a year-on-year increase of 4.6%[27] - The company reported a decrease in sales expenses to CNY 133,286,139.03 in Q1 2022 from CNY 144,055,029.38 in Q1 2021, a reduction of 7.5%[28] - Research and development expenses for Q1 2022 amounted to CNY 14,730,302.82, up from CNY 11,344,978.86 in Q1 2021, marking a 30.5% increase[28] Other Financial Activities - The company has applied for a bank loan of up to RMB 30,000,000, with RMB 19,000,000 already drawn down[17] - The company is in the process of planning a major asset restructuring through a share issuance[21] - The first phase of the employee stock ownership plan is under consideration and requires shareholder approval[20] - The company did not conduct an audit for the Q1 report, as indicated in the audit report[34]